Key points are not available for this paper at this time.
The gut microbiota is fundamental to human health, contributing to nutrient metabolism, immune regulation and protection against pathogens. Disturbances in this microbial community, often caused by antibiotic use, poor diet or infections, can disrupt intestinal homeostasis and predispose individuals to gastrointestinal disorders. Restoring this balance has become a major therapeutic goal, with probiotics emerging as one of the most widely studied interventions. Probiotics exert their beneficial effects through multiple mechanisms, including strengthening the intestinal barrier, adhering to mucosal surfaces to prevent pathogen colonization, competing for nutrients and receptor sites, producing antimicrobial substances, and modulating host immune responses. By acting at the interface of the host and its microbiota, probiotics can influence both local gut function and systemic health outcomes. Clinical studies have demonstrated the potential of probiotics in managing gastrointestinal conditions such as antibiotic-associated diarrhea, Helicobacter pylori infection, acute gastroenteritis, necrotizing enterocolitis, irritable bowel syndrome and AIDS-associated diarrhea. Evidence suggests that therapeutic benefits are strain specific, underscoring the importance of precise strain selection for targeted outcomes. However, variability in host microbiota composition contributes to inconsistent clinical results and safety concerns remain for vulnerable populations such as immunocompromised patients. Future research must address these challenges through large scale, well controlled trials that clarify strain dependent mechanisms and establish standardized recommendations. Advances in microbiome science also highlight the potential of next generation probiotics such as Faecalibacterium prausnitzii and Akkermansia muciniphila, which may extend benefits beyond conventional strains. In conclusion, probiotics represent a promising adjunct to conventional therapies for gastrointestinal disorders. With further progress in standardization and safety validation, they may become reliable and personalized tools for promoting gut and overall health. © 2025 Society of Chemical Industry.
Rana et al. (Sat,) studied this question.